Kidney Disease Risk and Your Genetics

By the ExomeDNA Research Team

Kidney disease risk describes a person's inherited likelihood of developing conditions that impair the kidneys' ability to filter waste from the blood. Genome-wide studies have associated variants near genes including APOL1 and TCF7L2 with susceptibility to nephritis and related renal conditions. Understanding the genetic landscape of kidney disease can help individuals make informed decisions about monitoring kidney health in consultation with a qualified clinician.

What is kidney disease risk?

Kidney disease risk refers to a person's susceptibility to developing conditions that progressively reduce the kidneys' ability to remove waste products and excess fluid from the bloodstream. The category encompassed by this trait includes nephritis (inflammation of the kidneys), nephrosis (non-inflammatory kidney damage), and renal sclerosis (scarring of kidney tissue). Together, these conditions account for a significant portion of chronic kidney disease burden worldwide.

The kidneys perform essential filtering tasks continuously, processing large volumes of blood around the clock. When filtering structures are chronically damaged — whether through immune-mediated processes, genetic variation, metabolic stress, or a combination of these factors — waste accumulates and normal blood chemistry is disrupted. Early-stage kidney changes often proceed without noticeable symptoms, making awareness of susceptibility factors particularly valuable for proactive health monitoring.

Kidney disease is rarely caused by a single gene. Rather, common genetic variants across multiple genomic regions each contribute a modest increment to overall susceptibility. Rare and common variants in certain genes — notably APOL1 — can contribute substantially, particularly in populations with West African ancestry.

The genetics behind kidney disease risk

Large-scale genome-wide association studies have identified multiple independent genetic signals associated with nephritis, nephrosis, and renal sclerosis (et al., 2024; PMID 39024449).

APOL1 — apolipoprotein L1 — stands out among the genes with the strongest genetic evidence for kidney disease associations. The protein encoded by this gene circulates in blood as a component of high-density lipoprotein particles, where it plays a role in lipid transport. Variants in APOL1 have been extensively studied in the context of kidney health. Research demonstrates that certain variant combinations — found more commonly in individuals with West African ancestry — are associated with substantially higher susceptibility to kidney conditions including focal segmental glomerulosclerosis and hypertension-attributed kidney disease.

APOL1 and kidney disease susceptibility: APOL1 variants show among the strongest genetic associations with nephritis and renal sclerosis in genome-wide studies. Carriers of two risk-associated APOL1 variants face a substantially greater likelihood of developing kidney conditions compared to the general population baseline, according to population genetics research.

TCF7L2 — transcription factor 7-like 2 — provides another genetic signal in this analysis. TCF7L2 is most widely studied in the context of type 2 diabetes, where it is one of the most replicated genetic associations known. Its role in metabolic signaling pathways also intersects with kidney biology: metabolic stress, elevated blood glucose, and downstream inflammatory processes represent established contributors to chronic kidney disease progression.

Multiple genomic loci in kidney disease genetics: The genetic architecture of kidney disease risk in this analysis involves signals across multiple chromosomes, suggesting that diverse biological pathways — immune response, lipid processing, and metabolic regulation — each contribute to overall susceptibility.

Other genes in the genomic neighborhood of the strongest associated signals include CELSR1, PDE4D, APOL5, and FTO. CELSR1 (cadherin EGF LAG seven-pass G-type receptor 1) encodes a membrane protein involved in cell-cell signaling and planar cell polarity. PDE4D (phosphodiesterase 4D) regulates cyclic AMP pathways relevant to inflammation and tissue repair. APOL5 shares structural and functional features with APOL1 and sits on the same chromosomal region at 22q13, making the locus a convergence point for apolipoprotein-related kidney biology. FTO (fat mass and obesity associated) is involved in metabolic processes and has associations across a wide range of metabolic traits that intersect with kidney health through downstream pathways.

What the research says about kidney disease and genetics

Genome-wide association analyses have progressively clarified the genetic architecture of kidney disease. The most recent large-scale study in this area identified independent signals across multiple genomic regions, each with distinct candidate genes (et al., 2024; PMID 39024449).

The evidence base is rated Robust — reflecting both the statistical consistency of the signals and the biological plausibility of the candidate genes. This means multiple independent replication datasets have confirmed these associations, and the candidate genes participate in biological pathways known to influence kidney physiology. The Robust rating indicates this is among the better-characterized areas of complex disease genetics.

It is important to understand that genetic associations at the population level do not determine individual outcomes. The variant combinations that raise susceptibility in genome-wide studies are common in the population; many individuals carrying these variants never develop significant kidney disease, while kidney disease also occurs in individuals without these variants. Non-genetic factors — including blood pressure management, blood glucose control, hydration, medication use, and infections — interact with genetic predisposition to shape long-term kidney health outcomes.

For more information on how genetic association evidence is evaluated, see ExomeDNA's methodology page (/methodology).

Research base: Robust.

How kidney disease risk affects you

Understanding your genetic profile in relation to kidney disease provides one layer of context for a broader health picture. Genetic susceptibility information is most useful when combined with clinical monitoring — blood tests for kidney function markers such as creatinine and estimated glomerular filtration rate (eGFR), along with urine tests for protein or albumin levels.

The APOL1 gene story is particularly relevant for individuals with African ancestry, where variant combinations that confer increased susceptibility are relatively common in the population. Research consistently documents that carriers of two risk-associated APOL1 variants face substantially higher susceptibility to certain kidney conditions compared to the general population baseline. Awareness of this genetic context can support timely discussions with a clinician about appropriate monitoring frequency and lifestyle optimization.

Kidney health also intersects strongly with metabolic health. Blood pressure and blood glucose levels are among the most modifiable factors affecting long-term kidney function. Genetic susceptibility information does not change the value of these lifestyle and clinical parameters — it underscores why they matter for individuals across ancestry backgrounds.

Kidney function monitoring markers: eGFR (estimated glomerular filtration rate) and urine albumin-to-creatinine ratio are the primary clinical markers used to track kidney health over time. These tests can detect early changes before symptoms appear, making periodic monitoring valuable for individuals with genetic susceptibility signals in this category.

Working with your kidney disease risk profile

Genetic susceptibility information is best understood as a conversation starter with your healthcare provider, not a standalone assessment. For those whose ExomeDNA profile shows a variant pattern associated with higher genetic susceptibility to kidney disease, this context is worth bringing to a physician — not a cause for alarm in isolation.

Practical steps that support kidney health at the general population level are well-established: maintaining healthy blood pressure, managing blood glucose levels, staying adequately hydrated, avoiding prolonged use of nephrotoxic medications (such as non-steroidal anti-inflammatory drugs taken regularly without clinical guidance), and not smoking. These lifestyle factors influence kidney health regardless of genetic background.

For individuals who carry high-confidence genetic signals in this category, discussing monitoring frequency with a primary care provider or nephrologist represents a reasonable and proactive approach. Kidney function tests are simple, widely available, and provide early detection of changes in kidney filtration efficiency before symptoms develop. Standard kidney panels typically take just a blood draw and urine sample.

This page is informational only. For health decisions, consult a qualified clinician.

Related traits and genes

Kidney disease risk intersects biologically with several other health traits tracked by ExomeDNA. Closely related traits include type 2 diabetes susceptibility, blood pressure regulation, and metabolic syndrome risk — each of which shares both genetic signals and physiological pathways with kidney function.

The APOL1 gene also appears in research on cardiovascular traits, reflecting its role in HDL biology and lipid metabolism. TCF7L2, which ranks among the top candidate genes in this analysis, is one of the most replicated genetic associations with type 2 diabetes risk known from population genetics — underscoring the convergent biology between metabolic and kidney health.

For individuals interested in the full genetic landscape of kidney-adjacent biology, ExomeDNA's Metabolism and Hormones and Health and Longevity categories include traits covering blood glucose regulation, insulin sensitivity, blood pressure, and related biomarkers that collectively shape kidney function over time.

Frequently asked questions

What does it mean to have a genetic susceptibility signal for kidney disease?

It means that genome-wide studies have identified variants near specific genes — including APOL1 and TCF7L2 — that are statistically associated with higher rates of kidney disease in population studies. This is population-level epidemiological information, not a personal prediction. Many people with similar genetic variant profiles never develop significant kidney disease, and many factors beyond genetics shape individual outcomes.

Is APOL1 only relevant for certain ancestry groups?

The variant combinations in APOL1 most strongly associated with kidney disease susceptibility are found at higher frequency in individuals with West African ancestry. However, APOL1 is a gene present across all human populations, and its role in kidney biology is relevant broadly. Research continues to characterize variant effects across diverse ancestry groups, and population-specific considerations are increasingly integrated into kidney health guidelines.

How does kidney disease risk relate to type 2 diabetes genetically?

Several genes overlap between kidney disease and type 2 diabetes genetics, including TCF7L2. This reflects the clinical reality that diabetes is a leading cause of chronic kidney disease worldwide — metabolic stress from elevated blood glucose progressively damages kidney filtering structures over time, linking these two disease categories at both the biological and genetic levels.

What lifestyle factors most influence kidney health?

Blood pressure control and blood glucose management have the strongest evidence base for kidney health preservation over time. Adequate hydration, avoiding regular overuse of non-steroidal anti-inflammatory drugs, not smoking, and maintaining a healthy weight are also well-supported by population health research. These factors influence kidney outcomes regardless of genetic background.

Should I get kidney function tests based on this genetic information?

Genetic susceptibility information can be useful context to bring to your physician. Kidney function tests — including creatinine, eGFR, and urine albumin — are widely available and non-invasive. Whether and how frequently to test is a clinical decision best made with your healthcare provider, who can consider your full health picture alongside genetic context.

References

et al. (2024). Genome-wide association study of nephritis, nephrosis, and renal sclerosis. PMID 39024449.

Data sources: Genetic variant associations from GWAS Catalog; gene-to-trait mapping from population-level GWAS data; ClinVar pathogenicity annotations from NCBI ClinVar; gene functional annotations from NCBI Gene.

Written by Scott Peeples, BS Biomedical Sciences · ExomeDNA Founder. Reviewed by the ExomeDNA Science Team.

This does not constitute a clinical evaluation, treatment recommendation, or clinical genetic test. ExomeDNA's genetic reports are for wellness and educational purposes only.